Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207025 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00207025 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants.
The verdict
NCT00207025, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.
Interventions
- DRUG BMS-275183
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207025
The ClinicalTrials.gov registry entry for NCT00207025 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-275183 is the first listed.
NCT00207025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207025 about?
NCT00207025 is a clinical study titled "A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies". The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.
What is the current status of trial NCT00207025?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00207025?
The interventions under investigation include: BMS-275183 (DRUG).
Who is sponsoring clinical trial NCT00207025?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.